Isaac Cheng - Jan 6, 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Director
Signature: /s/ Joshua B. Cohen, as Attorney-in-Fact for Isaac Cheng
Stock symbol: AMLX
Transactions as of: Jan 6, 2022
Transactions value $: $0
Form type: 3
Date filed: 1/6/2022, 04:09 PM
Next filing: Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Ownership	Footnotes
holding	AMLX	Series A Preferred Stock	Jan 6, 2022	Common Stock	1.41M	See Footnote	F1, F2
holding	AMLX	Series B Preferred Stock	Jan 6, 2022	Common Stock	6.41M	See Footnote	F1, F2
holding	AMLX	Series C-1 Preferred Stock	Jan 6, 2022	Common Stock	974K	See Footnote	F1, F2
holding	AMLX	Series C-2 Preferred Stock	Jan 6, 2022	Common Stock	1.62M	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A, Series B, Series C-1 and Series C-2 preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date.
F2	These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares.

Content

Each share of Series A, Series B, Series C-1 and Series C-2 preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date.

These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares.